5%+ stake

Baxter International (BAX): FMR LLC now owns 6.8% of BAX as a passive investor 6.8%

FMR LLC now owns 6.8% of BAX as a passive investor.

6.8%
Stake
34.8M
Shares owned
Stake as of
Dec 31, 2025
Filed
Feb 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  2. Oct 31, 2025CongressDisclosed sale of BAX — reported range $1,001 - $15,000
  3. Nov 5, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 5, 2025, Alok Sonig notified Baxter International Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a company in the healthcare industry.”
  4. Nov 13, 20255% stakeDodge & Cox reported a passive stake (13G) of 11.2%
  5. Nov 24, 2025Government · Federal Register ruleMedicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
  6. Nov 25, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
  7. Nov 28, 2025FDARecall: SIGMA Spectrum Infusion Pump, Model/Catalog Number: 35700BAX2
  8. Dec 3, 2025Court · District Court, N.D. IllinoisSecurities lawsuit filed: City of Hallandale Beach Police Officers' and Firefighters' Personnel Retirement Trust v. Baxter International, Inc.
  9. Dec 4, 2025Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 2 more items)
  10. Dec 16, 2025FDAFDA device clearance: Welch Allyn FlexiPort Blood Pressure Cuffs (FlexiPort Blood Pressure Cuffs)
  11. Dec 22, 2025FDARecall: Sterile Water for Irrigation, 250 mL, Single-Dose Plastic Bottle, Rx Only, Baxter Healthcare Corporation Deerfield, IL 60015 NDC: 0338-0004-02.

What came next

  1. Jan 13, 2026FDARecall: Brand Name: Spectrum IQ Product Name: Infusion Pump Model/Catalog Number: 3570009 Software Version: N/A Product Description: Infusion Pump, one unit per carton…
  2. Jan 16, 2026FDAFDA device clearance: WAVE Clinical Platform (2.0.000)
  3. Jan 21, 20265% stakePZENA INVESTMENT MANAGEMENT LLC reported a passive stake (13G) of 13.8%
  4. Jan 21, 20265% stakeBlackRock Portfolio Management LLC reported a passive stake (13G) of 8.7%
  5. Feb 5, 20265% stakeFMR LLC reported a passive stake (13G) of 6.8%
  6. Feb 10, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On February 10, 2026, Baxter International Inc. (the “Company”) appointed Michael R. McDonnell to its Board of Directors (the “Board”), effective February 13, 2026.”
  7. Feb 18, 2026FDARecall: Blue Ventilator Adapter Module, single-patient use circuit, Product Code M07937. Accessory to Baxter Volara Respiratory Therapy system.
  8. Feb 18, 2026FDARecall: Brand Name: Welch Allyn, Inc. Product Name: Welch Allyn Spot Vision Screener VS100 Model/Catalog Number: VS100 Software Version: Software version 3.2.0.1 Produ…
  9. Feb 26, 2026FDAFDA drug approval: Phytonadione
  10. Mar 15, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 16, 2026, Baxter International Inc. (the “Company”) announced that, as of such date (the “Transition Date”), Joel Grade’s service as Executive Vice President and Chief Financial Officer (“CFO”) of the Company has ceased and, as of such date, Mr. Grade has transitioned into a non-executive officer role and will continue employment with the Company in an advisory capacity through April 30, 2026.”
  11. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  12. Mar 30, 2026FDAFDA drug approval: Epinephrine
  13. Apr 3, 2026FDAFDA drug approval: Phenylephrine Hydrochloride
  14. Apr 15, 2026FDAFDA drug approval: Dexmedetomidine Hydrochloride
  15. Apr 21, 2026FDARecall: Adapter for Head Positioning, Model/Catalog Number: 1739994, when used in conjunction with the side rails of the Upper Back Section H V U component (product co…
  16. Apr 21, 20265% stakePZENA INVESTMENT MANAGEMENT LLC reported a passive stake (13G) of 12.7%
  17. Apr 22, 2026FDARecall: Brand Name: Exacta Mix Product Name: Vented Micro-Volume Inlet Model/Catalog Number: H938175 Product Description: Tubing sets with push-on connector on one end…
  18. Apr 27, 20265% stakeBlackRock, Inc. reported a passive stake (13G) of 6.4%
  19. Apr 29, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  20. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.4%
View the official recordSEC Schedule 13G

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Baxter International

For Baxter International, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BAX page.

How this filing works

Explore the data

Common questions

What does this filing report about Baxter International (BAX) stock?

FMR LLC now owns 6.8% of BAX as a passive investor. Of the company, Schedule 13G (passive).

When did it happen, and when was it made public?

Stake as of: Dec 31, 2025. Filed: Feb 5, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Baxter International recently?

For Baxter International, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the BAX page.

Does this mean BAX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Baxter International

Everything OQRO holds on this company is on its BAX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data